Pregabalin Pfizer

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

pregabalin

Available from:

Upjohn EESV

ATC code:

N03AX16

INN (International Name):

pregabalin

Therapeutic group:

Anti-epilettiċi,

Therapeutic area:

Anxiety Disorders; Epilepsy

Therapeutic indications:

Newropatiku painPregabalin Pfizer huwa indikat għat-trattament tal-uġigħ nevrotiku periferali u ċentrali f'persuni adulti. EpilepsyPregabalin Pfizer huwa indikat bħala terapija aġġuntiva f'persuni adulti b'aċċessjonijiet parzjali bi jew mingħajr ġeneralizzazzjoni sekondarja. Ta'ansjetà ġeneralizzata DisorderPregabalin Pfizer huwa indikat għall-kura ta 'Disturb ta' Ansjetà Ġeneralizzata (GAD-generalised anxiety disorder) f'persuni adulti.

Product summary:

Revision: 29

Authorization status:

Awtorizzat

Authorization date:

2014-04-10

Patient Information leaflet

                                57
B. FULJETT TA’ TAGĦRIF
58
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
PREGABALIN PFIZER 25 MG KAPSULI IBSIN
PREGABALIN PFIZER 50 MG KAPSULI IBSIN
PREGABALIN PFIZER 75 MG KAPSULI IBSIN
PREGABALIN PFIZER 100 MG KAPSULI IBSIN
PREGABALIN PFIZER 150 MG KAPSULI IBSIN
PREGABALIN PFIZER 200 MG KAPSULI IBSIN
PREGABALIN PFIZER 225 MG KAPSULI IBSIN
PREGABALIN PFIZER 300 MG KAPSULI IBSIN
pregabalin
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TUŻA DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anki jekk ikollhom l-istess sinjali ta’ mard
bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT
:
1.
X’inhu Pregabalin Pfizer u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu Pregabalin Pfizer
3.
Kif għandek tieħu Pregabalin Pfizer
4.
Effetti sekondarji possibbli
5.
Kif taħżen Pregabalin Pfizer
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU PREGABALIN PFIZER U GĦALXIEX JINTUŻA
Pregabalin Pfizer jappartjeni għal grupp ta’ mediċini li jintużaw
għall-kura tal-epilessija, l-uġigħ
nevrotiku u d-Disturb ta’ Ansjetà Ġeneralizzata (GAD - Generalised
Anxiety Disorder) fl-adulti.
UĠIGĦ NEVROTIKU PERIFERALI U ĊENTRALI:
Pregabalin Pfizer jintuża sabiex jiġi kkurat uġigħ fit-tul
ikkawżat minn ħsara fin-nervituri. Hemm numru ta’ mard li jista’
jikkaġuna wġigħ nevrotiku
periferali, bħad-dijabete jew il-ħruq ta’ Sant’Antnin.
Is-sensazzjonijiet ta’ uġigħ li wieħed iħoss jistgħu
jiġu deskritti bħala sħana, ħruq, tektik, uġigħ li jiġri minn
parti għal oħra tal-ġisem, tniffid, uġigħ
qawwi, bugħawwieġ, weġgħat, 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Pregabalin Pfizer 25 mg kapsuli ibsin
Pregabalin Pfizer 50 mg kapsuli ibsin
Pregabalin Pfizer 75 mg kapsuli ibsin
Pregabalin Pfizer 100 mg kapsuli ibsin
Pregabalin Pfizer 150 mg kapsuli ibsin
Pregabalin Pfizer 200 mg kapsuli ibsin
Pregabalin Pfizer 225 mg kapsuli ibsin
Pregabalin Pfizer 300 mg kapsuli ibsin
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Pregabalin Pfizer 25 mg kapsuli ibsin
Kull kapsula iebsa fiha 25 mg ta’ pregabalin.
_ _
_ _
Pregabalin Pfizer 50 mg kapsuli ibsin
Kull kapsula iebsa fiha 50 mg ta’ pregabalin.
_ _
_ _
Pregabalin Pfizer 75 mg kapsuli ibsin
Kull kapsula iebsa fiha 75 mg ta’ pregabalin.
_ _
Pregabalin Pfizer 100 mg kapsuli ibsin
Kull kapsula iebsa fiha 100 mg ta’ pregabalin.
_ _
_ _
Pregabalin Pfizer 150 mg kapsuli ibsin
Kull kapsula iebsa fiha 150 mg ta’ pregabalin.
_ _
_ _
Pregabalin Pfizer 200 mg kapsuli ibsin
Kull kapsula iebsa fiha 200 mg ta’ pregabalin.
_ _
_ _
Pregabalin Pfizer 225 mg kapsuli ibsin
Kull kapsula iebsa fiha 225 mg ta’ pregabalin.
_ _
_ _
Pregabalin Pfizer 300 mg kapsuli ibsin
Kull kapsula iebsa fiha 300 mg ta’ pregabalin.
_ _
_ _
Eċċipjenti b’effett magħruf
Pregabalin Pfizer 25 mg kapsuli ibsin
Kull kapsula iebsa fiha ukoll 35 mg lactose monohydrate.
_ _
_ _
Pregabalin Pfizer 50 mg kapsuli ibsin
Kull kapsula iebsa fiha ukoll 70 mg lactose monohydrate.
_ _
Pregabalin Pfizer 75 mg kapsuli ibsin
Kull kapsula iebsa fiha ukoll 8.25 mg lactose monohydrate.
_ _
Pregabalin Pfizer 100 mg kapsuli ibsin
Kull kapsula iebsa fiha ukoll 11 mg lactose monohydrate.
_ _
Pregabalin Pfizer 150 mg kapsuli ibsin
Kull kapsula iebsa fiha ukoll 16.50 mg lactose monohydrate.
_ _
Pregabalin Pfizer 200 mg kapsuli ibsin
Kull kapsula iebsa fiha ukoll 22 mg lactose monohydrate.
_ _
3
Pregabalin Pfizer 225 mg kapsuli ibsin
Kull kapsula iebsa fiha ukoll 24.75 mg lactose monohydrate.
_ _
Pregabalin Pfizer 300 mg kapsuli ibsin
Kull kapsula iebsa fiha ukoll 33 mg lactose monohydrate.
_ _
_ _
Għal-li
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 12-01-2024
Public Assessment Report Public Assessment Report Bulgarian 07-05-2014
Patient Information leaflet Patient Information leaflet Spanish 12-01-2024
Public Assessment Report Public Assessment Report Spanish 07-05-2014
Patient Information leaflet Patient Information leaflet Czech 12-01-2024
Public Assessment Report Public Assessment Report Czech 07-05-2014
Patient Information leaflet Patient Information leaflet Danish 12-01-2024
Public Assessment Report Public Assessment Report Danish 07-05-2014
Patient Information leaflet Patient Information leaflet German 12-01-2024
Public Assessment Report Public Assessment Report German 07-05-2014
Patient Information leaflet Patient Information leaflet Estonian 12-01-2024
Public Assessment Report Public Assessment Report Estonian 07-05-2014
Patient Information leaflet Patient Information leaflet Greek 12-01-2024
Public Assessment Report Public Assessment Report Greek 07-05-2014
Patient Information leaflet Patient Information leaflet English 12-01-2024
Public Assessment Report Public Assessment Report English 07-05-2014
Patient Information leaflet Patient Information leaflet French 12-01-2024
Public Assessment Report Public Assessment Report French 07-05-2014
Patient Information leaflet Patient Information leaflet Italian 12-01-2024
Public Assessment Report Public Assessment Report Italian 07-05-2014
Patient Information leaflet Patient Information leaflet Latvian 12-01-2024
Public Assessment Report Public Assessment Report Latvian 07-05-2014
Patient Information leaflet Patient Information leaflet Lithuanian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 12-01-2024
Public Assessment Report Public Assessment Report Lithuanian 07-05-2014
Patient Information leaflet Patient Information leaflet Hungarian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 12-01-2024
Public Assessment Report Public Assessment Report Hungarian 07-05-2014
Patient Information leaflet Patient Information leaflet Dutch 12-01-2024
Public Assessment Report Public Assessment Report Dutch 07-05-2014
Patient Information leaflet Patient Information leaflet Polish 12-01-2024
Public Assessment Report Public Assessment Report Polish 07-05-2014
Patient Information leaflet Patient Information leaflet Portuguese 12-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 12-01-2024
Public Assessment Report Public Assessment Report Portuguese 07-05-2014
Patient Information leaflet Patient Information leaflet Romanian 12-01-2024
Public Assessment Report Public Assessment Report Romanian 07-05-2014
Patient Information leaflet Patient Information leaflet Slovak 12-01-2024
Public Assessment Report Public Assessment Report Slovak 07-05-2014
Patient Information leaflet Patient Information leaflet Slovenian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 12-01-2024
Public Assessment Report Public Assessment Report Slovenian 07-05-2014
Patient Information leaflet Patient Information leaflet Finnish 12-01-2024
Public Assessment Report Public Assessment Report Finnish 07-05-2014
Patient Information leaflet Patient Information leaflet Swedish 12-01-2024
Public Assessment Report Public Assessment Report Swedish 07-05-2014
Patient Information leaflet Patient Information leaflet Norwegian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 12-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 12-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 12-01-2024
Patient Information leaflet Patient Information leaflet Croatian 12-01-2024
Public Assessment Report Public Assessment Report Croatian 07-05-2014

Search alerts related to this product